These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 36100324

  • 1. A vancomycin resistance-associated WalK(S221P) mutation attenuates the virulence of vancomycin-intermediate Staphylococcus aureus.
    Rao Y, Peng H, Shang W, Hu Z, Yang Y, Tan L, Li M, Zhou R, Rao X.
    J Adv Res; 2022 Sep; 40():167-178. PubMed ID: 36100324
    [Abstract] [Full Text] [Related]

  • 2. WalK(S221P), a naturally occurring mutation, confers vancomycin resistance in VISA strain XN108.
    Peng H, Hu Q, Shang W, Yuan J, Zhang X, Liu H, Zheng Y, Hu Z, Yang Y, Tan L, Li S, Hu X, Li M, Rao X.
    J Antimicrob Chemother; 2017 Apr 01; 72(4):1006-1013. PubMed ID: 27999059
    [Abstract] [Full Text] [Related]

  • 3. A novel mutation of walK confers vancomycin-intermediate resistance in methicillin-susceptible Staphylococcus aureus.
    Zhu J, Liu B, Shu X, Sun B.
    Int J Med Microbiol; 2021 Feb 01; 311(2):151473. PubMed ID: 33445057
    [Abstract] [Full Text] [Related]

  • 4. Reconstruction of the Vancomycin-Susceptible Staphylococcus aureus Phenotype From a Vancomycin-Intermediate S. aureus XN108.
    Peng H, Rao Y, Yuan W, Zheng Y, Shang W, Hu Z, Yang Y, Tan L, Xiong K, Li S, Zhu J, Hu X, Hu Q, Rao X.
    Front Microbiol; 2018 Feb 01; 9():2955. PubMed ID: 30546356
    [Abstract] [Full Text] [Related]

  • 5. VraR Binding to the Promoter Region of agr Inhibits Its Function in Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA.
    Dai Y, Chang W, Zhao C, Peng J, Xu L, Lu H, Zhou S, Ma X.
    Antimicrob Agents Chemother; 2017 May 01; 61(5):. PubMed ID: 28289032
    [Abstract] [Full Text] [Related]

  • 6. Evolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKR.
    Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, Bell J, Coombs G, Bennett-Wood V, Porter JL, Robins-Browne R, Davies JK, Seemann T, Stinear TP.
    PLoS Pathog; 2011 Nov 01; 7(11):e1002359. PubMed ID: 22102812
    [Abstract] [Full Text] [Related]

  • 7. Genetic pathway in acquisition and loss of vancomycin resistance in a methicillin resistant Staphylococcus aureus (MRSA) strain of clonal type USA300.
    Gardete S, Kim C, Hartmann BM, Mwangi M, Roux CM, Dunman PM, Chambers HF, Tomasz A.
    PLoS Pathog; 2012 Feb 01; 8(2):e1002505. PubMed ID: 22319446
    [Abstract] [Full Text] [Related]

  • 8. Repeated Exposure of Vancomycin to Vancomycin-Susceptible Staphylococcus aureus (VSSA) Parent Emerged VISA and VRSA Strains with Enhanced Virulence Potentials.
    Nguyen A, Roy JJS, Kim JH, Yun KH, Lee W, Kim KK, Kim T, Chaurasia AK.
    J Microbiol; 2024 Jul 01; 62(7):535-553. PubMed ID: 38814539
    [Abstract] [Full Text] [Related]

  • 9. Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes.
    Dietrich A, Steffens U, Gajdiss M, Boschert AL, Dröge JK, Szekat C, Sass P, Malik IT, Bornikoel J, Reinke L, Maček B, Franz-Wachtel M, Nieselt K, Harbig T, Scherlach K, Brötz-Oesterhelt H, Hertweck C, Sahl HG, Bierbaum G.
    Microbiol Spectr; 2022 Oct 26; 10(5):e0256722. PubMed ID: 36173303
    [Abstract] [Full Text] [Related]

  • 10. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus.
    Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC.
    Antimicrob Agents Chemother; 2012 Nov 26; 56(11):5845-51. PubMed ID: 22948864
    [Abstract] [Full Text] [Related]

  • 11. Investigating the effect of an identified mutation within a critical site of PAS domain of WalK protein in a vancomycin-intermediate resistant Staphylococcus aureus by computational approaches.
    Baseri N, Najar-Peerayeh S, Bakhshi B.
    BMC Microbiol; 2021 Sep 02; 21(1):240. PubMed ID: 34474665
    [Abstract] [Full Text] [Related]

  • 12. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus.
    Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, Hishinuma T, Hiramatsu K.
    Antimicrob Agents Chemother; 2011 Aug 02; 55(8):3870-81. PubMed ID: 21628539
    [Abstract] [Full Text] [Related]

  • 13. Decreased vancomycin susceptibility in Staphylococcus aureus caused by IS256 tempering of WalKR expression.
    McEvoy CR, Tsuji B, Gao W, Seemann T, Porter JL, Doig K, Ngo D, Howden BP, Stinear TP.
    Antimicrob Agents Chemother; 2013 Jul 02; 57(7):3240-9. PubMed ID: 23629723
    [Abstract] [Full Text] [Related]

  • 14. Modulating activity of vancomycin and daptomycin on the expression of autolysis cell-wall turnover and membrane charge genes in hVISA and VISA strains.
    Cafiso V, Bertuccio T, Spina D, Purrello S, Campanile F, Di Pietro C, Purrello M, Stefani S.
    PLoS One; 2012 Jul 02; 7(1):e29573. PubMed ID: 22253738
    [Abstract] [Full Text] [Related]

  • 15. Vancomycin-intermediate Staphylococcus aureus isolates are attenuated for virulence when compared with susceptible progenitors.
    Cameron DR, Lin YH, Trouillet-Assant S, Tafani V, Kostoulias X, Mouhtouris E, Skinner N, Visvanathan K, Baines SL, Howden B, Monk IR, Laurent F, Stinear TP, Howden BP, Peleg AY.
    Clin Microbiol Infect; 2017 Oct 02; 23(10):767-773. PubMed ID: 28396035
    [Abstract] [Full Text] [Related]

  • 16. Staphylococcus aureus response and adaptation to vancomycin.
    Fait A, Silva SF, Abrahamsson JÅH, Ingmer H.
    Adv Microb Physiol; 2024 Oct 02; 85():201-258. PubMed ID: 39059821
    [Abstract] [Full Text] [Related]

  • 17. The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus.
    Hort M, Bertsche U, Nozinovic S, Dietrich A, Schrötter AS, Mildenberger L, Axtmann K, Berscheid A, Bierbaum G.
    Microbiol Spectr; 2021 Oct 31; 9(2):e0052821. PubMed ID: 34668723
    [Abstract] [Full Text] [Related]

  • 18. The effect of subinhibitory concentration of chlorhexidine on the evolution of vancomycin-intermediate Staphylococcus aureus and the induction of mutations in walKR and vraTSR systems.
    Baseri N, Najar-Peerayeh S, Bakhshi B.
    Infect Genet Evol; 2021 Jan 31; 87():104628. PubMed ID: 33171303
    [Abstract] [Full Text] [Related]

  • 19. Development of an Amplicon Nanopore Sequencing Strategy for Detection of Mutations Conferring Intermediate Resistance to Vancomycin in Staphylococcus aureus Strains.
    Moller AG, Petit RA, Davis MH, Read TD.
    Microbiol Spectr; 2023 Feb 14; 11(1):e0272822. PubMed ID: 36688645
    [Abstract] [Full Text] [Related]

  • 20. Methicillin-resistant and vancomycin-intermediate Staphylococcus aureus colonizing patients and intensive care unit environment: virulence profile and genetic variability.
    Veloso JO, Lamaro-Cardoso J, Neves LS, Borges LFA, Pires CH, Lamaro L, Guerreiro TC, Ferreira EMA, André MCP.
    APMIS; 2019 Nov 14; 127(11):717-726. PubMed ID: 31407405
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.